Enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design

Int J Nanomedicine. 2015 Oct 13:10:6469-76. doi: 10.2147/IJN.S89364. eCollection 2015.

Abstract

Aripiprazole is considered as a third-generation antipsychotic drug with excellent therapeutic efficacy in controlling schizophrenia symptoms and was the first atypical anti-psychotic agent to be approved by the US Food and Drug Administration. Formulation of nanoemulsion-containing aripiprazole was carried out using high shear and high pressure homogenizers. Mixture experimental design was selected to optimize the composition of nanoemulsion. A very small droplet size of emulsion can provide an effective encapsulation for delivery system in the body. The effects of palm kernel oil ester (3-6 wt%), lecithin (2-3 wt%), Tween 80 (0.5-1 wt%), glycerol (1.5-3 wt%), and water (87-93 wt%) on the droplet size of aripiprazole nanoemulsions were investigated. The mathematical model showed that the optimum formulation for preparation of aripiprazole nanoemulsion having the desirable criteria was 3.00% of palm kernel oil ester, 2.00% of lecithin, 1.00% of Tween 80, 2.25% of glycerol, and 91.75% of water. Under optimum formulation, the corresponding predicted response value for droplet size was 64.24 nm, which showed an excellent agreement with the actual value (62.23 nm) with residual standard error <3.2%.

Keywords: D-optimal mixture design; antipsychotic drug; bipolar I disorder; optimization formulation; schizoaffective disorder.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antipsychotic Agents / chemistry*
  • Antipsychotic Agents / therapeutic use*
  • Aripiprazole / chemistry*
  • Aripiprazole / therapeutic use*
  • Capsules
  • Chemistry, Pharmaceutical / methods*
  • Emulsions
  • Nanomedicine / methods*
  • Schizophrenia / drug therapy*

Substances

  • Antipsychotic Agents
  • Capsules
  • Emulsions
  • Aripiprazole